Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03GII
|
||||
| Former ID |
DIB001670
|
||||
| Drug Name |
SR-26831
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] | Terminated | [1] | ||
| Company |
Sanofi
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H23ClNO3S+
|
||||
| Canonical SMILES |
c1(sc2c(c1)C[N+](Cc1c(Cl)cccc1)(CC2)[O-])OC(=O)C(C)(C)C
|
||||
| CAS Number |
CAS 139995-67-8
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Leukocyte elastase | Target Info | Modulator | [2] | |
| KEGG Pathway | Transcriptional misregulation in cancer | ||||
| Systemic lupus erythematosus | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| C-MYB transcription factor network | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Human Complement System | |||||
| Degradation of collagen | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001260) | ||||
| REF 2 | Biochemical and pharmacological activities of SR 26831, a potent and selective elastase inhibitor. J Pharmacol Exp Ther. 1992 Feb;260(2):809-16. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.